Tredje AP fonden reduced its position in shares of Mednax, Inc (NYSE:MD) by 26.9% during the fourth quarter, Holdings Channel reports. The firm owned 18,995 shares of the company’s stock after selling 6,993 shares during the period. Tredje AP fonden’s holdings in Mednax were worth $1,266,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. First Bank & Trust purchased a new position in shares of Mednax during the fourth quarter worth about $175,000. 1st Global Advisors Inc. purchased a new position in shares of Mednax during the third quarter worth about $205,000. Bronfman E.L. Rothschild L.P. boosted its position in shares of Mednax by 8.3% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,209 shares of the company’s stock worth $213,000 after buying an additional 247 shares during the period. Capital Fund Management S.A. boosted its position in shares of Mednax by 6.0% in the third quarter. Capital Fund Management S.A. now owns 3,721 shares of the company’s stock worth $247,000 after buying an additional 210 shares during the period. Finally, Argent Capital Management LLC boosted its position in shares of Mednax by 9.2% in the third quarter. Argent Capital Management LLC now owns 3,900 shares of the company’s stock worth $258,000 after buying an additional 330 shares during the period. 99.16% of the stock is currently owned by institutional investors and hedge funds.
Mednax, Inc (NYSE:MD) traded up 0.20% during mid-day trading on Friday, hitting $69.92. 64,469 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $68.74 and its 200-day moving average price is $66.12. The stock has a market cap of $6.49 billion, a PE ratio of 20.03 and a beta of 0.67. Mednax, Inc has a 12 month low of $59.36 and a 12 month high of $76.96.
This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/mednax-inc-md-position-reduced-by-tredje-ap-fonden/1208311.html
Mednax (NYSE:MD) last released its earnings results on Tuesday, February 7th. The company reported $1.00 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.06. The company earned $831 million during the quarter, compared to analysts’ expectations of $842.15 million. Mednax had a net margin of 10.21% and a return on equity of 13.59%. The firm’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.13 earnings per share. Equities analysts expect that Mednax, Inc will post $4.25 EPS for the current fiscal year.
“Mednax, Inc (MD) Position Reduced by Tredje AP fonden” was first published by Zolmax and is owned by of Zolmax. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright & trademark law. The original version of this article can be read at https://zolmax.com/investing/mednax-inc-md-position-reduced-by-tredje-ap-fonden/1208311.html.
A number of research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a research note on Wednesday, December 28th. Jefferies Group LLC reissued a “hold” rating and issued a $63.00 price objective on shares of Mednax in a research note on Wednesday, February 8th. They noted that the move was a valuation call. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Mednax in a research note on Friday, December 9th. They issued a “neutral” rating and a $66.00 price objective on the stock. Raymond James Financial, Inc. cut shares of Mednax from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 27th. Finally, Mizuho decreased their price objective on shares of Mednax from $79.00 to $69.00 and set a “buy” rating on the stock in a research note on Friday, October 28th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $71.56.
In related news, CFO Vivian Lopez-Blanco sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $70.95, for a total transaction of $709,500.00. Following the sale, the chief financial officer now directly owns 74,261 shares in the company, valued at approximately $5,268,817.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Md Carlo A. Waldemar sold 5,334 shares of the company’s stock in a transaction that occurred on Thursday, February 9th. The shares were sold at an average price of $67.90, for a total transaction of $362,178.60. Following the sale, the director now owns 16,589 shares in the company, valued at $1,126,393.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,628 shares of company stock worth $2,787,118. Corporate insiders own 2.40% of the company’s stock.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.